Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Published byScott Patrick Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean."— Presentation transcript:

1 Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent timepoint compared with the baseline value and stratified by randomized treatment group with associated 95% confidence intervals. The reported P-values are for the comparison between changes with sacubitril/valsartan vs. enalapril. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, ehz240, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2 Ratio of the geometric mean concentration of urinary cyclic guanosine 3′5′ monophosphate at each timepoint ... Figure 2 Ratio of the geometric mean concentration of urinary cyclic guanosine 3′5′ monophosphate at each timepoint compared with baseline and stratified by randomized treatment group with associated 95% confidence intervals. The reported P-values are for the comparison between changes with sacubitril/valsartan vs. enalapril. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, ehz240, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3 Kaplan–Meier-estimated rates at week 8 of cardiovascular death and rehospitalization for heart failure (84 ... Figure 3 Kaplan–Meier-estimated rates at week 8 of cardiovascular death and rehospitalization for heart failure (84 events) with sacubitril/valsartan or enalapril using an intention-to-treat analysis stratified by baseline hsTnT, sST2, and NT-proBNP concentration ≥ median (high) vs. < median (low). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, ehz240, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Take home figure Relative effect of sacubitril/valsartan vs
Take home figure Relative effect of sacubitril/valsartan vs. enalapril on hsTnT, sST2 and NT-proBNP calculated from the ratio ... Take home figure Relative effect of sacubitril/valsartan vs. enalapril on hsTnT, sST2 and NT-proBNP calculated from the ratio of the geometric means from baseline to week 8 for each biomarker. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the European Society of Cardiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Eur Heart J, ehz240, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean."

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Detection of Bacteriuria by Canine Olfaction

From: Detection of Bacteriuria by Canine Olfaction
Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.

Abstract From: Lung transplantation after ex vivo lung perfusion in two Scandinavian centres Eur J Cardiothorac Surg. Published online October 29, 2018.
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
Figure 4 Change in plaque burden, plaque area, and plaque composition according to wall shear stress. (A and B) Change ... Figure 4 Change in plaque burden,

Figure 4 Change in plaque burden, plaque area, and plaque composition according to wall shear stress. (A and B) Change ... Figure 4 Change in plaque burden,
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
FIGURE 1 Flow chart of patient enrollment and exclusion

FIGURE 1 Flow chart of patient enrollment and exclusion

Similar presentations

Ads by Google